Professor Mark Febbraio is a National Health and Medical Research Council of Australia Research Investigator and the Head of the Cellular and Molecular Metabolism Laboratory within the Drug Discovery Program at Monash Institute of Pharmaceutical Sciences, Monash University Australia. He is also the Founder of the recently incorporated company Celesta Therapeutics. His research is focussed on understanding mechanisms associated with exercise, obesity, type 2 diabetes and cancer and his aim is to develop novel drugs to treat lifestyle related diseases. He has authored over 280 peer reviewed papers in leading journals and has over 45,000 career citations. Throughout his career, he has won many prestigious awards including the A K McIntyre Prize for significant contributions to Australian Physiological Science (1999), the Kellion Award for the Australian Diabetes Society (2017), The Eureka Scientific Prize (2020), The GSK Award for Research Excellence (2020), The Endocrinology Society UK International Medal (2021) the Kirsten and Freddy Johansen Rigshospitalet International Award, Denmark (2022) and The Faculty of Pharmacy and Pharmaceutical Sciences, Monash University Award for Excellence in Research (2022).
« Go Back